- Home
- LFWD vs NLSP Comparison
LFWD vs NLSP Comparison
Compare LFWD & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFWD
- NLSP
- Stock Information
- Founded
- LFWD 2001
- NLSP 2015
- Country
- LFWD Israel
- NLSP Switzerland
- Employees
- LFWD N/A
- NLSP N/A
- Industry
- LFWD
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- LFWD
- NLSP Health Care
- Exchange
- LFWD NYSE
- NLSP Nasdaq
- Market Cap
- LFWD 11.8M
- NLSP 12.4M
- IPO Year
- LFWD 2014
- NLSP 2021
- Fundamental
- Price
- LFWD $0.60
- NLSP $2.68
- Analyst Decision
- LFWD Strong Buy
- NLSP
- Analyst Count
- LFWD 3
- NLSP 0
- Target Price
- LFWD $9.00
- NLSP N/A
- AVG Volume (30 Days)
- LFWD 1.2M
- NLSP 325.4K
- Earning Date
- LFWD 08-14-2025
- NLSP 07-07-2025
- Dividend Yield
- LFWD N/A
- NLSP N/A
- EPS Growth
- LFWD N/A
- NLSP N/A
- EPS
- LFWD N/A
- NLSP N/A
- Revenue
- LFWD $25,414,000.00
- NLSP N/A
- Revenue This Year
- LFWD $12.04
- NLSP N/A
- Revenue Next Year
- LFWD $40.58
- NLSP N/A
- P/E Ratio
- LFWD N/A
- NLSP N/A
- Revenue Growth
- LFWD 41.92
- NLSP N/A
- 52 Week Low
- LFWD $0.50
- NLSP $1.30
- 52 Week High
- LFWD $4.77
- NLSP $16.00
- Technical
- Relative Strength Index (RSI)
- LFWD 13.67
- NLSP 62.59
- Support Level
- LFWD $0.50
- NLSP $2.19
- Resistance Level
- LFWD $1.15
- NLSP $2.54
- Average True Range (ATR)
- LFWD 0.09
- NLSP 0.19
- MACD
- LFWD -0.05
- NLSP -0.01
- Stochastic Oscillator
- LFWD 10.79
- NLSP 57.89
About LFWD REWALK ROBOTICS LTD
Lifeward Ltd is a medical device company that designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering functional and health benefits in clinical settings as well as in the home and community. Its product offerings are the ReWalk Exoskeleton, the ReStore Exo-Suit, the MyoCycle FES bikes, and AlterG Anti-Gravity systems. It operates through markets in the United States, Israel, and Germany.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.